It's always in the presentations, see the "Baseline Patient Characteristics" slide. Our trial patient population is about 50% APO4 carriers.
Some higher statistics here: This doesn't mean APO4 isn't correlated at all with effectiveness, just not as a solitary factor. It could be, for example, that the combination of gene X and APO4 is the effectiveness factor. But Anavex is not sophisticated enough to detect that themselves. Hence they hired Ariana.
Market Data 
Markets 
AI
